Gilead to purchase Pharmasset at $11 billion to drive hepatitis C pipeline
Gilead Sciences has announced the completion of a final agreement to buy Pharmasset for approximately $11 billion, to expand its pipeline of hepatitis C virus treatments. The deal represents an 89-percent premium to Pharmasset's closing share price on November 18.
According to Gilead the deal, due to close in the first quarter of 2012, has been unanimously agreed by Pharmasset's board. Gilead expects the purchase to lower earnings to 2014 but assist gains in 2015 and beyond.
Find Gilead company analysis at Reportbuyer.com:
Gilead Sciences Inc-Detailed Product Pipeline Gilead Sciences Inc-Detailed product pipeline report contains detailed information on pipelines by phase and therapeutic indication as well as management information,deals and alliances and recent news on the company including key milestones.
Gilead's newly approved drug Complera Gilead's newly approved drug Complera, the second triple combination once-a-day Pill Intended for Untreated HIV Patients is unlikely to displace its own market-leading drug, Atripla' is a featured article highlighting the discovery of the Complera and its added benefits from its own market-leading drug, Atripla. This report features the current therapeutics available in HIV therapy.
Gilead Sciences Inc-Deals & Alliances Report This report contains the company's contact information, business summary, company details, tables, graphs and listings of the number of deals by deal category (product, technology, miscellaneous), stage of development, list of partners, deal types (licensing, marketing, etc.), top deals by deal value, and partner information.
press@reportbuyer.com
t. 44 (0) 20 7060 7474
Report Buyer the online store for global business information. The website now lists more than 200,000 company overviews, market research reports, industry studies and business books from over 300 specialist publishers. Thousands of professionals from across the world make ReportBuyer.com their first choice in their search for quality business insight.
Tags: